Advertisement

Molecular Biology Reports

, Volume 46, Issue 4, pp 4001–4008 | Cite as

The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer

  • Mukaddes Avsar
  • Makbule Tambas
  • Zubeyde Yalniz
  • Demet Akdeniz
  • Seref Bugra Tuncer
  • Seda Kilic
  • Ozge Sukruoglu Erdogan
  • Rumeysa Ciftci
  • Nergiz Dagoglu
  • Sezai Vatansever
  • Hulya YaziciEmail author
Original Article

Abstract

The Fibulins are a recently discovered family of extracellular matrix proteins. In this study, expression levels of the fibulin-2 (FBLN2) gene and its role in the formation of different metastatic foci were investigated in lung cancer patients. We analyzed 106 lung cancer patients and eight paraffin-embedded tissues, and 27 ethnical-, age- and sex-matched healthy controls for expression levels of the FBLN2 gene. cDNAs obtained from the enriched epithelial cells of peripheral blood lymphocytes and tumor tissues of patients were amplified with specific primers for the target FBLN2 gene and HPRT1 housekeeping gene using quantitative real-time polymerase chain reaction. FBLN2 gene expression levels of the enriched epithelial cells of peripheral blood lymphocytes were found to be decreased approximately twofold in all subsets of patients compared to healthy controls. Our results indicate a significant difference between patient subgroups and controls [F(4.124) = 14.846, p0.05] among patient subgroups: bone metastases versus non-metastatic groups (p = 0.997), bone versus brain metastases (p = 0994), bone metastases versus two primary tumors (p = 0.999), brain metastases versus two primary tumors (p = 0.999), brain metastases versus non-metastatic (p = 0.755), non-metastatic versus two primary tumors (p = 0.996), non-metastatic versus all other metastatic patients (p = 0.731). Moreover, we found a 50-fold upregulation of FBLN2 gene expression in paraffin-embedded tissues compared with the enriched epithelial cells of peripheral blood lymphocytes of patients. In the study, the enriched epithelial cells of peripheral blood lymphocytes of decreased FBLN2 expression was found to be correlated with metastasis. The fibulin-2 molecules might induce the metastatic potential through interaction with the other molecules in the microenvironment, nevertheless, it is needed further research whether the importance of FBLN2 on lung cancer oncogenesis and as a biomarker for metastatic lung cancer.

Keywords

Fibulin-2 (FBLN2) Gene expression ctRNA Lung cancer Metastasis 

Notes

Acknowledgements

All authors thank the participants and the Research Fund of Istanbul University for funding (Project No. 24255) to study.

Funding

The present work was supported by the Research Fund of Istanbul University. Project No. 24255.

Compliance with ethical standards

Ethical approval

All human participant involving procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was granted by the Local and Clinical Research Ethics Committee of Istanbul Medical Faculty, and all participants (patients and controls) provided written informed consent in accordance with the Declaration of Helsinki (Protocol Number: 333-962).

Informed consent

The informed consents were obtained from all participants that were included in the study. The study was approved by the Ethics Committee of Istanbul Medical Faculty in Istanbul University (Ethical Approval No: 2012/333-962).

Research involving human and animal participants

This article contains no studies conducted with animals.

Conflict of interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917.  https://doi.org/10.1002/ijc.25516 CrossRefGoogle Scholar
  2. 2.
    Carney DN (2002) Lung cancer–time to move on from chemotherapy. N Engl J Med 346:126–128.  https://doi.org/10.1056/nejm200201103460211346/2/126 CrossRefPubMedGoogle Scholar
  3. 3.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594.  https://doi.org/10.4065/83.5.584 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12:89–96.  https://doi.org/10.1006/scbi.2001.0416 CrossRefPubMedGoogle Scholar
  5. 5.
    Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1:49–52CrossRefPubMedGoogle Scholar
  6. 6.
    Kopper L, Timar J (2005) Genomics of lung cancer may change diagnosis, prognosis and therapy. Pathol Oncol Res 11:5–10CrossRefPubMedGoogle Scholar
  7. 7.
    Amos CI, Xu W, Spitz MR (1999) Is there a genetic basis for lung cancer susceptibility. Recent Results Cancer Res 151:3–12CrossRefPubMedGoogle Scholar
  8. 8.
    de Vega S, Iwamoto T, Yamada Y (2009) Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66:1890–1902.  https://doi.org/10.1007/s00018-009-8632-6 CrossRefPubMedGoogle Scholar
  9. 9.
    Gallagher WM, Currid CA, Whelan LC (2005) Fibulins and cancer: friend or foe? Trends Mol Med 11:336–340.  https://doi.org/10.1016/j.molmed.2005.06.001 CrossRefPubMedGoogle Scholar
  10. 10.
    Twal WO et al (2001) Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114:4587–4598PubMedGoogle Scholar
  11. 11.
    Timpl R, Sasaki T, Kostka G, Chu ML (2003) Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4:479–489.  https://doi.org/10.1038/nrm1130nrm1130 CrossRefPubMedGoogle Scholar
  12. 12.
    Miosge N, Gotz W, Sasaki T, Chu ML, Timpl R, Herken R (1996) The extracellular matrix proteins fibulin-1 and fibulin-2 in the early human embryo. Histochem J 28:109–116CrossRefPubMedGoogle Scholar
  13. 13.
    Obaya AJ, Rua S, Moncada-Pazos A, Cal S (2012) The dual role of fibulins in tumorigenesis. Cancer Lett 325:132–138.  https://doi.org/10.1016/j.canlet.2012.06.019 CrossRefPubMedGoogle Scholar
  14. 14.
    Pan TC, Sasaki T, Zhang RZ, Fassler R, Timpl R, Chu ML (1993) Structure and expression of fibulin-2, a novel extracellular matrix protein with multiple EGF-like repeats and consensus motifs for calcium binding. J Cell Biol 123:1269–1277CrossRefPubMedGoogle Scholar
  15. 15.
    Yi CH, Smith DJ, West WW, Hollingsworth MA (2007) Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 170:1535–1545.  https://doi.org/10.2353/ajpath.2007.060478 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54.  https://doi.org/10.1038/ng1060ng1060 CrossRefPubMedGoogle Scholar
  17. 17.
    Alcendor DJ, Knobel S, Desai P, Zhu WQ, Hayward GS (2011) KSHV regulation of fibulin-2 in Kaposi’s sarcoma: implications for tumorigenesis. Am J Pathol 179:1443–1454.  https://doi.org/10.1016/j.ajpath.2011.05.024 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Dunwell TL et al (2009) Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 4:185–193CrossRefPubMedGoogle Scholar
  19. 19.
    Law EW et al (2012) Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 31:728–738.  https://doi.org/10.1038/onc.2011.272 CrossRefPubMedGoogle Scholar
  20. 20.
    Senapati S, Gnanapragassam VS, Moniaux N, Momi N, Batra SK (2012) Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene 31:3346–3356.  https://doi.org/10.1038/onc.2011.505 CrossRefPubMedGoogle Scholar
  21. 21.
    Ulazzi L et al (2007) Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer 6:17.  https://doi.org/10.1186/1476-4598-6-17 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hergeth SP, Aicher WK, Essl M, Schreiber TD, Sasaki T, Klein G (2008) Characterization and functional analysis of osteoblast-derived fibulins in the human hematopoietic stem cell niche. Exp Hematol 36:1022–1034.  https://doi.org/10.1016/j.exphem.2008.03.013 CrossRefPubMedGoogle Scholar
  23. 23.
    Langer C, Hirsh V (2010) Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:4–11.  https://doi.org/10.1016/j.lungcan.2009.08.020 CrossRefPubMedGoogle Scholar
  24. 24.
    Sasaki T, Wiedemann H, Matzner M, Chu ML, Timpl R (1996) Expression of fibulin-2 by fibroblasts and deposition with fibronectin into a fibrillar matrix. J Cell Sci 109(12):2895–2904PubMedGoogle Scholar
  25. 25.
    Utani A, Nomizu M, Yamada Y (1997) Fibulin-2 binds to the short arms of laminin-5 and laminin-1 via conserved amino acid sequences. J Biol Chem 272:2814–2820CrossRefPubMedGoogle Scholar
  26. 26.
    Gu YC, Nilsson K, Eng H, Ekblom M (2000) Association of extracellular matrix proteins fibulin-1 and fibulin-2 with fibronectin in bone marrow stroma. Br J Haematol 109:305–313CrossRefPubMedGoogle Scholar
  27. 27.
    Hill VK et al (2010) Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 9:51.  https://doi.org/10.1186/1476-4598-9-51 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Baird BN et al (2013) Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS ONE 8:e67054.  https://doi.org/10.1371/journal.pone.0067054 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tsuda T et al (2012) Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction. J Mol Cell Cardiol 52:273–282.  https://doi.org/10.1016/j.yjmcc.2011.11.001 CrossRefPubMedGoogle Scholar
  30. 30.
    Guadall A et al (2011) Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1alpha)-dependent mechanism. J Biol Chem 286:7093–7103.  https://doi.org/10.1074/jbc.M110.162917 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Mukaddes Avsar
    • 1
  • Makbule Tambas
    • 2
  • Zubeyde Yalniz
    • 1
  • Demet Akdeniz
    • 1
  • Seref Bugra Tuncer
    • 1
  • Seda Kilic
    • 1
  • Ozge Sukruoglu Erdogan
    • 1
  • Rumeysa Ciftci
    • 3
  • Nergiz Dagoglu
    • 2
  • Sezai Vatansever
    • 3
  • Hulya Yazici
    • 1
    Email author
  1. 1.Department of Cancer Genetics, Institute of OncologyIstanbul UniversityIstanbulTurkey
  2. 2.Department of Radiation Oncology, Institute of OncologyIstanbul UniversityIstanbulTurkey
  3. 3.Department of Medical Oncology, Institute of OncologyIstanbul UniversityIstanbulTurkey

Personalised recommendations